Oxurion is a biotech research company specializing in developing treatments for retinal diseases, specifically Geographic Atrophy and Age-related Macular Degeneration. The company focuses on innovative approaches to eye care.

Oxurion

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Oxurion NV

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 28, 2024 6:07 PM	0ad594ab
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 28, 2024 6:07 PM	f2d80c2e
crunchbase trigger	general	Nov 27, 2024 12:50 PM	0219220a
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 28, 2024 6:07 PM	37d20aa8
news basic	general	Sep 28, 2024 6:07 PM	b2cba886
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:OXURION

Oxurion

Last Close

0.32

25/11 09:23

Market Cap

2.46M

Beta: -

Volume Today

39.22K

Avg: -